Loss of Anti-TNF Treatment Response Common in Crohn's Disease
(MedPage Today) -- Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors lost response by the third year of treatment, a population-based observational study showed.
Fully 60... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 22, 2024 Category: Gastroenterology Source Type: news
Patients with suspected bowel disease could refer themselves for scans, saving time on long waiting lists
Currently, patients with suspected Crohn's disease or ulcerative colitis, known together as inflammatory bowel disease (IBD), have to see a GP before they can be referred to hospital for a diagnosis. (Source: the Mail online | Health)
Source: the Mail online | Health - April 21, 2024 Category: Consumer Health News Source Type: news
FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance Therapy FDA OKs Sub-Q Vedolizumab for Crohn's Maintenance Therapy
Subcutaneous administration of vedolizumab is now approved for maintenance therapy in adults with moderate to severe active Crohn ' s disease after induction therapy with intravenous vedolizumab.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2024 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news
This vitamin deficiency can cause forgetfulness and mimic symptoms of dementia
About 5.8 million people in the U.S. have Alzheimer's disease and related dementias, giving these life-altering illnesses a wide impact across the country. But while it can be devastating when a loved one shows signs of memory loss, doctors say you shouldn’t automatically assume they have…#b12 #vitaminb12 #scottkaiser #santamonica #nih #deborahcohen #dcn #crohn #amitsachdev #kaiser (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2024 Category: Consumer Health News Source Type: news
Upadacitinib Provides Rapid Relief in Crohn's Disease Upadacitinib Provides Rapid Relief in Crohn's Disease
Patients with Crohn ' s disease achieved rapid symptom relief with upadacitinib, including those with prior biologic failure.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 3, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details
Thursday, Bristol Myers Squibb & Co BMY announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE trial program of Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease. The study did not meet its…#zeposia #ozanimod #crohn #yellowstone #bristolmyerssquibb #nsclc #krasg12c #krazati #orr #fda (Source: Reuters: Health)
Source: Reuters: Health - April 1, 2024 Category: Consumer Health News Source Type: news
Hundreds of thousands of Crohn's patients will get a vital drug quicker to avoid drastic invasive surgery
Crohn's patients have been offered a drug called infliximab, which has been shown to reduce painful symptoms and limit severe complications. (Source: the Mail online | Health)
Source: the Mail online | Health - March 31, 2024 Category: Consumer Health News Source Type: news
Bristol Myers' Bowel Disease Drug Fails in Late-stage Study Bristol Myers' Bowel Disease Drug Fails in Late-stage Study
Bristol Myers Squibb said on Thursday its experimental drug to treat Crohn ' s disease, a chronic inflammatory bowel condition, did not help patients achieve disease remission...Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 28, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
PFCD: Are Outcomes Better With Combined Medical-Surgical Tx? PFCD: Are Outcomes Better With Combined Medical-Surgical Tx?
Anti-TNF therapy alone was noninferior to a combination of surgery and anti-TNF therapy in fistula healing in patients with perianal fistulizing Crohn ' s, a meta-analysis showed.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 28, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
She beat a rare liver cancer – and now works with her father to find more cures
Cancer scientist decides to study the tumour that once afflicted his small daughter – and now her work is adding to his project’s successElana Simon was 10 years old when she started to experience severe pains in her abdomen. For two years, puzzled doctors put forward diagnoses including lactose intolerance, Crohn ’s disease and stress. It was not until 2008 that they pinpointed the real cause. Elana was suffering from fibrolamellar carcinoma(FLC), a rare, usually lethal, form of liver cancer.“In a way, it was comforting to have a word for what was wrong with me after so much confusion about my condition,” Elana ...
Source: Guardian Unlimited Science - March 16, 2024 Category: Science Authors: Robin McKie Science Editor Tags: Cancer research Medical research Science UK news Source Type: news
US Insurers Out of Step With IBD Treatment Guidelines US Insurers Out of Step With IBD Treatment Guidelines
Most US insurance companies require patients to fail conventional therapies for Crohn ' s disease and ulcerative colitis before they will cover a biologic agent, contrary to treatment guidelines.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news
Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a study published online Feb. 22 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2024 Category: Pharmaceuticals Source Type: news
Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are two of the hottest pharmaceutical stocks of the past three years. Both companies have marked returns far in excess of the market's, thanks to popular demand for their freshly launched medications that treat obesity as well as type 2 diabetes.…#novonordisk #nvo #elililly #lly #ozempic #fda #zepbound #mounjaro #crohn #ozempicandwegovy (Source: Reuters: Health)
Source: Reuters: Health - March 4, 2024 Category: Consumer Health News Source Type: news
Risankizumab Beats Ustekinumab for Previously Treated Crohn's
(MedPage Today) -- Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis factor (TNF) inhibitor, the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news
Why Is Teva Pharma Stock Trading Higher Today?
Friday, Alvotech ALVO and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd TEVA, announced the FDA approved Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to AbbVie Inc’s ABBV Humira. The biosimilar is indicated for adult rheumatoid arthritis,…#alvotech #tevapharmaceuticals #fda #abbvieincs #abbvhumira #crohn #humira #teva #tevapharma #splitspeculations (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2024 Category: Consumer Health News Source Type: news
